About Us
Established in June 2021 in Shanghai, China. Brise Pharma stands as a clinical stage biopharmaceutical company with a major focus on the development of innovative and highly differentiated treatment solutions for severe pain conditions, especially for addressing issues such as migraine, inflammatory pain, and neuropathic pain.
Brise Pharma was originally formed by a group of veterans with an average of over 15 years extensive experience in drug R&D with global perspective, ranging from preclinical study, clinical development to financing, investment and company operations.
Our Aim
Our aim is to provide safe, effective, and accessible pain treatment solutions to patients in China and worldwide struggling with debilitating pain conditions through our restless innovation.
Our Vision
Based on solid global networks with key opinion leaders in the therapeutic areas, our well-balanced R&D pipelines based on optimally diversified modalities and our excellent research team with profound achievements, Brise Pharma strives to become a global leader in innovative pain disease treatment.
Our Approach
Our approach combines deep industry expertise and an extensive network of clinical KOLs to drive more effective and efficient research, and enable better therapies to patients. We are building a balanced pipeline based on clinically validated targets utilizing optimal modalities and technologies as well as original innovations. We are also better positioned to offer solutions to patients via external collaborations.
Development Pipeline
Contact Us
Office and labs - Shanghai
Brise Pharmaceuticals Co. Ltd.
2555 Xiupu Road, Building E3, 8F
Pudong New District, Shanghai, China
Email: Contact@brisepharma.com